Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy

被引:34
作者
van Ingen, Jakko
Boeree, Martin
Janssen, Matthijs
Ullmann, Erik
de Lange, Wiel
de Haas, Petra
Dekhuijzen, Richard
van Soolingen, Dick
机构
[1] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pulm Dis 454, NL-6500 HB Nijmegen, Netherlands
[2] Natl Inst Publ Hlth & Environm, Natl Mycobacteria Reference Lab, Bilthoven, Netherlands
[3] Rijnstate Hosp, Arnhem, Netherlands
来源
NATURE CLINICAL PRACTICE RHEUMATOLOGY | 2007年 / 3卷 / 07期
关键词
adalimumab; atypical mycobacteria; atypical mycobacterial infections; Mycobacterium szulgai; rheumatoid arthritis;
D O I
10.1038/ncprheum0538
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background A 54-year-old man with a 22-year history of rheumatoid arthritis and an 8-year history of chronic obstructive pulmonary disease presented with dyspnea on exertion, nonproductive cough and fatigue of 1 month's duration. His medication at presentation consisted of etanercept, azathioprine, naproxen and inhaled fluticasone and salbutamol. Investigations At presentation, the patient underwent physical examination, chest X-ray and high-resolution CT, blood tests, and bronchoalveolar lavage fluid analysis including auramine stains and gene sequence analysis of cultured Mycobacterium szulgai. The patient underwent minithoracotomy after 6 months, and bronchoalveolar lavage fluid analysis, culture and chest X-ray after 18 months. Further chest imaging and culture of sputum samples were performed another year later. Diagnosis Pulmonary M. szulgai infection. Management Triple drug therapy with rifampicin, ethambutol hydrochloride and clarithromycin. Anti-tumor necrosis factor treatment was continued.
引用
收藏
页码:414 / 419
页数:6
相关论文
共 16 条
[1]   Mycobacterium szulgai infection of the lung: Case report and review of an unusual pathogen [J].
Benator, DA ;
Kan, V ;
Gordin, FM .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1997, 313 (06) :346-351
[2]  
Campbell I, 2000, THORAX, V55, P210
[3]   Treatment of sarcoidosis with infliximab [J].
Doty, JD ;
Mazur, JE ;
Judson, MA .
CHEST, 2005, 127 (03) :1064-1071
[4]   Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management [J].
Gardam, MA ;
Keystone, EC ;
Menzies, R ;
Manners, S ;
Skamene, E ;
Long, R ;
Vinh, DC .
LANCET INFECTIOUS DISEASES, 2003, 3 (03) :148-155
[5]   Development of sarcoidosis during etanercept therapy [J].
Gonzalez-Lopez, Marcos A. ;
Blanco, Ricardo ;
Gonzalez-Vela, M. Carmen ;
Fernandez-Llaca, Hector ;
Rodriguez-Valverde, Vicente .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (05) :817-820
[6]   Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis [J].
Ishige, I ;
Usui, Y ;
Takemura, T ;
Eishi, Y .
LANCET, 1999, 354 (9173) :120-123
[7]   Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: Comparison of thin-section CT and histopathologic findings [J].
Jeong, YJ ;
Lee, KS ;
Koh, WJ ;
Han, J ;
Kim, TS ;
Kwon, OJ .
RADIOLOGY, 2004, 231 (03) :880-886
[8]   Infliximab for rheumatoid arthritis in a patient with tuberculosis [J].
Matsumoto, Tomoshige ;
Tanaka, Toshio ;
Kawase, Ichiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07) :740-741
[9]   Mycobacterium abscessus infection after use of tumor necrosis factor α inhibitor therapy:: case report and review of infectious complications associated with tumor necrosis factor α inhibitor use [J].
Mufti, AH ;
Toye, BW ;
Mckendry, RRJ ;
Angel, JB .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 53 (03) :233-238
[10]   Experience with etanercept in an academic medical center: Are infection rates increased? [J].
Phillips, K ;
Husni, ME ;
Karlson, EW ;
Coblyn, JS .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (01) :17-21